Overview

Dulaglutide (Trulicity) is a long-acting GLP-1 receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus. As a fusion protein combining a modified GLP-1 analog with an Fc fragment, dulaglutide provides extended duration of action allowing for once-weekly subcutaneous administration. The medication has demonstrated robust efficacy in glycemic control, weight reduction, and cardiovascular risk reduction in extensive clinical trial programs.

The REWIND trial, one of the largest cardiovascular outcomes trials for GLP-1 receptor agonists, demonstrated that dulaglutide significantly reduced major adverse cardiovascular events by 12% compared to placebo over a median follow-up of 5.4 years. This cardiovascular benefit, combined with its favorable dosing schedule and safety profile, has established dulaglutide as a cornerstone therapy for type 2 diabetes management.

Mechanism of Action

Dulaglutide functions as a selective GLP-1 receptor agonist, mimicking the action of endogenous incretin hormones. Upon binding to GLP-1 receptors in pancreatic beta cells, it stimulates glucose-dependent insulin secretion, meaning insulin is only released when blood glucose levels are elevated. This mechanism significantly reduces the risk of hypoglycemia compared to insulin secretagogues.

The compound also suppresses glucagon release from pancreatic alpha cells in a glucose-dependent manner, reducing hepatic glucose output when inappropriate. Additionally, dulaglutide slows gastric emptying, promoting satiety and reducing postprandial glucose excursions. The medication's effects on the central nervous system contribute to appetite suppression and weight loss.

The Fc fusion design provides proteolytic stability and extends the elimination half-life to approximately 5 days, enabling once-weekly dosing. This is achieved through reduced renal clearance and protection from dipeptidyl peptidase-4 (DPP-4) degradation.

Research Summary

Dulaglutide has been extensively studied with over 10 major human clinical trials and numerous comparative effectiveness studies. The research demonstrates consistent efficacy and safety across diverse patient populations.

Key Studies

REWIND Trial (2019): This landmark cardiovascular outcomes trial enrolled 9,901 participants with type 2 diabetes and followed them for a median of 5.4 years. Dulaglutide 1.5 mg weekly reduced the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 12% (HR 0.88, 95% CI 0.79-0.99, p=0.026). Notably, 68.5% of participants had no established cardiovascular disease at baseline, demonstrating primary prevention benefits.

SUSTAIN-7 Comparison (2018): Head-to-head trial comparing dulaglutide 1.5 mg weekly with semaglutide 1.0 mg weekly in 1,201 participants. While both agents provided significant glycemic improvement from baseline, semaglutide demonstrated superior HbA1c reduction (-1.5% vs -1.1%) and greater weight loss (-4.6 kg vs -2.3 kg) at 40 weeks.

SURPASS-CVOT (2024-2025): Recent trials comparing dulaglutide with the newer agent tirzepatide have shown that while dulaglutide remains highly effective, tirzepatide provides superior glycemic control and weight loss. However, dulaglutide maintains its cardiovascular benefits and established safety profile.

Pediatric Studies (2022): A phase 3 trial in adolescents with type 2 diabetes demonstrated that dulaglutide 1.5 mg weekly significantly reduced HbA1c compared to placebo (-0.9% vs +0.6%) over 26 weeks, with a safety profile consistent with adult studies.

Dosage Guidelines

Dulaglutide is administered as a once-weekly subcutaneous injection using a pre-filled pen device. The medication is approved for use in adults and adolescents (≥10 years old) with type 2 diabetes.

Dose Escalation: If additional glycemic control is needed after 4 weeks on 0.75 mg, increase to 1.5 mg weekly. Further increases to 3.0 mg and 4.5 mg weekly may be considered based on clinical response and tolerability. Each dose increase should be separated by at least 4 weeks.

Special Populations: No dose adjustment is required for mild to moderate renal impairment. Use is not recommended in severe renal impairment or end-stage renal disease. No dose adjustment needed for hepatic impairment.

Safety Profile

Dulaglutide has demonstrated an excellent safety profile in extensive clinical trials involving over 20,000 patient-years of exposure. The medication is generally well-tolerated with most adverse effects being mild to moderate and gastrointestinal in nature.

Common Side Effects (>5% incidence):

• Nausea (21.1% vs 5.9% placebo)
• Diarrhea (13.7% vs 7.4% placebo)
• Vomiting (12.6% vs 3.9% placebo)
• Abdominal pain (9.6% vs 6.2% placebo)
• Decreased appetite (8.6% vs 2.9% placebo)

Serious Considerations:

• Pancreatitis: Rare but serious risk (0.1% incidence). Discontinue if acute pancreatitis is suspected
• Thyroid C-cell tumors: Theoretical risk based on rodent studies; contraindicated with personal/family history of medullary thyroid carcinoma
• Severe gastroparesis: May worsen in predisposed patients
• Hypoglycemia: Low risk when used alone, increased when combined with insulin or sulfonylureas

Injection Site Reactions: Mild reactions occur in approximately 1-2% of patients and typically resolve within days.

The cardiovascular safety profile is excellent, with the REWIND trial demonstrating significant cardiovascular benefits rather than risks.

Stacking

Dulaglutide is commonly used in combination with other diabetes medications as part of comprehensive glycemic management strategies.

Metformin + Dulaglutide: First-line combination for most patients. Complementary mechanisms with excellent safety profile. Metformin may help reduce GI side effects of dulaglutide.

SGLT-2 Inhibitors + Dulaglutide: Highly effective combination addressing multiple pathophysiologic defects in type 2 diabetes. The AWARD-10 trial demonstrated significant additional glycemic and weight benefits when dulaglutide was added to SGLT-2 inhibitor therapy.

Insulin + Dulaglutide: Effective for advanced diabetes requiring intensive management. Insulin doses typically need reduction when adding dulaglutide to prevent hypoglycemia. Combination provides complementary prandial and basal glucose control.

Avoid with other GLP-1 RAs: Concurrent use with other incretin-based therapies (semaglutide, liraglutide, etc.) is not recommended due to overlapping mechanisms and increased GI side effects.

DPP-4 Inhibitors: Not recommended in combination due to shared incretin pathway effects without additional benefit.

When used in combination therapy, careful monitoring for hypoglycemia is essential, particularly with insulin or sulfonylureas, and dose adjustments of concomitant medications may be necessary.

References

1. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. (2019). Lancet (London, England). DOI PubMed
2. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. (2024). American heart journal. DOI PubMed
3. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. (2025). The New England journal of medicine. DOI PubMed
4. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. (2018). The lancet. Diabetes & endocrinology. DOI PubMed
5. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. (2021). Molecular metabolism. DOI PubMed
6. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. (2025). Annals of internal medicine. DOI PubMed
7. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. (2022). The lancet. Diabetes & endocrinology. DOI PubMed
8. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. (2022). The New England journal of medicine. DOI PubMed
9. Effects of dulaglutide on alcohol consumption during smoking cessation. (2023). JCI insight. DOI PubMed
10. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. (2018). The lancet. Diabetes & endocrinology. DOI PubMed